Global Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Research Report 2024

Publication ID:

PB501241475

Publication Date:

January 24, 2024

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Alzheimer鈥檚 Disease Therapeutics and Diagnostics market was valued at US$ 6596.5 million in 2023 and is anticipated to reach US$ 8589.1 million by 2030, witnessing a CAGR of 3.8% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Alzheimer鈥檚 Disease Therapeutics and Diagnostics, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Alzheimer鈥檚 Disease Therapeutics and Diagnostics.
Report Scope
The Alzheimer鈥檚 Disease Therapeutics and Diagnostics market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Alzheimer鈥檚 Disease Therapeutics and Diagnostics market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Alzheimer鈥檚 Disease Therapeutics and Diagnostics companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
麻豆原创 Segmentation
By Company
Pfizer
Eisai
Novartis
Forest Laboratories
TauRx Therapeutics
AC Immune
Johnson & Johnson.
H. Lundbeck
Segment by Type
Diagnostics
Treatment
Segment by Application
麻豆原创ed Drugs
Pipeline Drugs
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Alzheimer鈥檚 Disease Therapeutics and Diagnostics companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Diagnostics
1.2.3 Treatment
1.3 麻豆原创 by Application
1.3.1 Global Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Growth by Application: 2019 VS 2023 VS 2030
1.3.2 麻豆原创ed Drugs
1.3.3 Pipeline Drugs
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Perspective (2019-2030)
2.2 Alzheimer鈥檚 Disease Therapeutics and Diagnostics Growth Trends by Region
2.2.1 Global Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Size by Region: 2019 VS 2023 VS 2030
2.2.2 Alzheimer鈥檚 Disease Therapeutics and Diagnostics Historic 麻豆原创 Size by Region (2019-2024)
2.2.3 Alzheimer鈥檚 Disease Therapeutics and Diagnostics Forecasted 麻豆原创 Size by Region (2025-2030)
2.3 Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Dynamics
2.3.1 Alzheimer鈥檚 Disease Therapeutics and Diagnostics Industry Trends
2.3.2 Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Drivers
2.3.3 Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Challenges
2.3.4 Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Alzheimer鈥檚 Disease Therapeutics and Diagnostics Players by Revenue
3.1.1 Global Top Alzheimer鈥檚 Disease Therapeutics and Diagnostics Players by Revenue (2019-2024)
3.1.2 Global Alzheimer鈥檚 Disease Therapeutics and Diagnostics Revenue 麻豆原创 Share by Players (2019-2024)
3.2 Global Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Alzheimer鈥檚 Disease Therapeutics and Diagnostics Revenue
3.4 Global Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Concentration Ratio
3.4.1 Global Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Alzheimer鈥檚 Disease Therapeutics and Diagnostics Revenue in 2023
3.5 Alzheimer鈥檚 Disease Therapeutics and Diagnostics Key Players Head office and Area Served
3.6 Key Players Alzheimer鈥檚 Disease Therapeutics and Diagnostics Product Solution and Service
3.7 Date of Enter into Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Alzheimer鈥檚 Disease Therapeutics and Diagnostics Breakdown Data by Type
4.1 Global Alzheimer鈥檚 Disease Therapeutics and Diagnostics Historic 麻豆原创 Size by Type (2019-2024)
4.2 Global Alzheimer鈥檚 Disease Therapeutics and Diagnostics Forecasted 麻豆原创 Size by Type (2025-2030)
5 Alzheimer鈥檚 Disease Therapeutics and Diagnostics Breakdown Data by Application
5.1 Global Alzheimer鈥檚 Disease Therapeutics and Diagnostics Historic 麻豆原创 Size by Application (2019-2024)
5.2 Global Alzheimer鈥檚 Disease Therapeutics and Diagnostics Forecasted 麻豆原创 Size by Application (2025-2030)
6 North America
6.1 North America Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Size (2019-2030)
6.2 North America Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Size by Country (2019-2024)
6.4 North America Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Size (2019-2030)
7.2 Europe Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Size by Country (2019-2024)
7.4 Europe Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Size (2019-2030)
8.2 Asia-Pacific Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Size by Region (2019-2024)
8.4 Asia-Pacific Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Size (2019-2030)
9.2 Latin America Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Size by Country (2019-2024)
9.4 Latin America Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Size (2019-2030)
10.2 Middle East & Africa Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Size by Country (2019-2024)
10.4 Middle East & Africa Alzheimer鈥檚 Disease Therapeutics and Diagnostics 麻豆原创 Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Pfizer
11.1.1 Pfizer Company Detail
11.1.2 Pfizer Business Overview
11.1.3 Pfizer Alzheimer鈥檚 Disease Therapeutics and Diagnostics Introduction
11.1.4 Pfizer Revenue in Alzheimer鈥檚 Disease Therapeutics and Diagnostics Business (2019-2024)
11.1.5 Pfizer Recent Development
11.2 Eisai
11.2.1 Eisai Company Detail
11.2.2 Eisai Business Overview
11.2.3 Eisai Alzheimer鈥檚 Disease Therapeutics and Diagnostics Introduction
11.2.4 Eisai Revenue in Alzheimer鈥檚 Disease Therapeutics and Diagnostics Business (2019-2024)
11.2.5 Eisai Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Alzheimer鈥檚 Disease Therapeutics and Diagnostics Introduction
11.3.4 Novartis Revenue in Alzheimer鈥檚 Disease Therapeutics and Diagnostics Business (2019-2024)
11.3.5 Novartis Recent Development
11.4 Forest Laboratories
11.4.1 Forest Laboratories Company Detail
11.4.2 Forest Laboratories Business Overview
11.4.3 Forest Laboratories Alzheimer鈥檚 Disease Therapeutics and Diagnostics Introduction
11.4.4 Forest Laboratories Revenue in Alzheimer鈥檚 Disease Therapeutics and Diagnostics Business (2019-2024)
11.4.5 Forest Laboratories Recent Development
11.5 TauRx Therapeutics
11.5.1 TauRx Therapeutics Company Detail
11.5.2 TauRx Therapeutics Business Overview
11.5.3 TauRx Therapeutics Alzheimer鈥檚 Disease Therapeutics and Diagnostics Introduction
11.5.4 TauRx Therapeutics Revenue in Alzheimer鈥檚 Disease Therapeutics and Diagnostics Business (2019-2024)
11.5.5 TauRx Therapeutics Recent Development
11.6 AC Immune
11.6.1 AC Immune Company Detail
11.6.2 AC Immune Business Overview
11.6.3 AC Immune Alzheimer鈥檚 Disease Therapeutics and Diagnostics Introduction
11.6.4 AC Immune Revenue in Alzheimer鈥檚 Disease Therapeutics and Diagnostics Business (2019-2024)
11.6.5 AC Immune Recent Development
11.7 Johnson & Johnson.
11.7.1 Johnson & Johnson. Company Detail
11.7.2 Johnson & Johnson. Business Overview
11.7.3 Johnson & Johnson. Alzheimer鈥檚 Disease Therapeutics and Diagnostics Introduction
11.7.4 Johnson & Johnson. Revenue in Alzheimer鈥檚 Disease Therapeutics and Diagnostics Business (2019-2024)
11.7.5 Johnson & Johnson. Recent Development
11.8 H. Lundbeck
11.8.1 H. Lundbeck Company Detail
11.8.2 H. Lundbeck Business Overview
11.8.3 H. Lundbeck Alzheimer鈥檚 Disease Therapeutics and Diagnostics Introduction
11.8.4 H. Lundbeck Revenue in Alzheimer鈥檚 Disease Therapeutics and Diagnostics Business (2019-2024)
11.8.5 H. Lundbeck Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Pfizer
Eisai
Novartis
Forest Laboratories
TauRx Therapeutics
AC Immune
Johnson & Johnson.
H. Lundbeck

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.